Syracuse, NY · Founded 2015 · Privately Held (backing)
Developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone. ZetaGen Therapeutics is based in Syracuse, NY and was founded in 2015. It was valued at $180 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $52.5 million across 4 recorded rounds; the latest was a $12.9 million early-stage round in Jan 2025.
PMV mark · valuation
$180.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$52.5M
Last round
Early Stage VC
Jan 2025
Cap table — not yet on record
ZetaGen Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of ZetaGen Therapeutics with a free account
·Watch ZetaGen Therapeutics: the Monday email on marks, rounds and moves
Where does ZetaGen Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across ZetaGen Therapeutics's 4 recorded funding rounds.
